Scandinavian Biopharma is pleased to announce the successful completion of its large pediatric Phase IIb trial for ETVAX®, a promising vaccine candidate against enterotoxigenic Escherichia coli (ETEC), commonly called traveler’s diarrhea, conducted in The Gambia.
Scandinavian Biopharma is pleased to announce another year of significant growth. For the full year 2023, the revenue increased by over 33 MSEK, corresponding an organic growth of 27%. The total revenue for 2023 amounted to 154 MSEK.
It is with great pleasure that we present another really good year of growth. The figures for the full year 2022 add up to an increase in sales equivalent to 30% in organic growth. In total, sales amount to approximately SEK 122 million. Our ETEC vaccine candidate, ETVAX, is about to enter phase 3.
At the annual PATH-hosed Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference, diarrhea is always the center of the conversation, and this year's gathering was no exception. During the 2022 VASE Conference in Washington, DC last week more than 300 experts traveled from around the world to learn about the latest enteric vaccine research.
All participants have received the third and final vaccination dose in our large randomized, placebo-controlled, and double-blind phase 2b study in The Gambia. The study includes 4 936 children aged 6-18 months. The overall goal of the study is to investigate the efficacy against moderate to severe diarrhea caused by ETEC.
Scandinavian Biopharma is now strengthening its organization by recruiting Anna Hill to the new position as Clinical Operations Manager. Anna will have the overall responsibility for the company's clinical development program and be responsible for ensuring that ongoing and future clinical trials are performed in a compliant and efficient manner.
The international global health nonprofit organization PATH and Scandinavian Biopharma have agreed to continue their collaboration to develop a novel vaccine candidate against diarrhea caused by ETEC. Impressive results obtained in a recently conducted clinical Phase I study triggered this decision. PATH supports the project by providing expertise, know-how, and financial resources.
Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine.The results are very encouraging. The vaccine was shown to be safe and elicited an intestinal immune response to the vaccine components. A new clinical phase-I study to document the safety and immunogenicity of the final composition vaccine has been initiated.